# Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

> **NCT01721603** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 2 (actual)

## Conditions studied

- BRAFV600E Melanoma Patients

## Interventions

- **DRUG:** Dabrafenib
- **PROCEDURE:** Gamma Knife Radiosurgery
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT01721603
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721603, "Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01721603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*